Case | HBS Case Collection | August 2013 (Revised October 2013)

MedImmune Ventures

by Richard G. Hamermesh and David Lane

Abstract

Ron Laufer is the new Senior Managing Director of MedImmune Ventures, the corporate venture capital arm of AstraZeneca, a leading pharmaceuticals firm. Laufer has to decide whether to pursue a high-potential, but very risky, early-stage investment. The decision Laufer will make will reflect his vision for MedImmune Ventures and more broadly the incentives he faces as a corporate venture capitalist.

Keywords: MedImmune; MedImmune Ventures; AstraZeneca; NeuProtect; corporate venturing; venture capital; biotechnology; venture investing; Venture Capital; Health Care and Treatment; Pharmaceutical Industry; Financial Services Industry; Biotechnology Industry; United States; Australia; Europe; London;

Citation:

Hamermesh, Richard G., and David Lane. "MedImmune Ventures." Harvard Business School Case 814-023, August 2013. (Revised October 2013.)